BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) saw unusually-strong trading volume on Wednesday . Approximately 1,775,462 shares were traded during mid-day trading, an increase of 74% from the previous session’s volume of 1,022,378 shares.The stock last traded at $5.01 and had previously closed at $4.95.

A number of equities research analysts have recently issued reports on BCRX shares. JPMorgan Chase & Co. reaffirmed a “hold” rating on shares of BioCryst Pharmaceuticals in a research note on Friday, August 5th. HC Wainwright reaffirmed a “buy” rating on shares of BioCryst Pharmaceuticals in a research note on Friday, August 5th. Jefferies Group upped their price objective on shares of BioCryst Pharmaceuticals from $2.00 to $3.00 and gave the company a “hold” rating in a research note on Friday, August 5th. FBR & Co reaffirmed a “buy” rating and issued a $6.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Wednesday, July 6th. Finally, JMP Securities cut shares of BioCryst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, August 4th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and five have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $8.60.

The company has a 50-day moving average of $3.28 and a 200 day moving average of $3.24. The company’s market capitalization is $368.46 million.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings data on Thursday, August 4th. The biotechnology company reported ($0.22) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.26) by $0.04. The firm earned $4.80 million during the quarter, compared to the consensus estimate of $3.92 million. BioCryst Pharmaceuticals’s quarterly revenue was down 81.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.06 EPS. Equities research analysts predict that BioCryst Pharmaceuticals Inc. will post ($1.04) earnings per share for the current fiscal year.

Several hedge funds have recently added to or reduced their stakes in the stock. Globeflex Capital L P purchased a new stake in BioCryst Pharmaceuticals during the fourth quarter worth approximately $1,241,000. Morgan Stanley boosted its stake in BioCryst Pharmaceuticals by 13.9% in the fourth quarter. Morgan Stanley now owns 103,804 shares of the biotechnology company’s stock worth $1,071,000 after buying an additional 12,646 shares in the last quarter. Finally, Jennison Associates LLC boosted its stake in BioCryst Pharmaceuticals by 1.8% in the fourth quarter. Jennison Associates LLC now owns 1,348,563 shares of the biotechnology company’s stock worth $13,917,000 after buying an additional 24,014 shares in the last quarter.

BioCryst Pharmaceuticals, Inc (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.